# Verici Dx gains greater reimbursement clarity for transplant diagnostics

- Link: https://www.directorstalkinterviews.com/verici-dx-gains-greater-reimbursement-clarity-for-transplant-diagnostics/4121257386
- Published: 2026-07-22T09:36:00+01:00
- Author: Amilia Stone

[Verici Dx](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)
has welcomed the final MolDx Local Coverage Determination for molecular testing 
in kidney, heart and lung transplantation.

The policy gives clearer guidance on when molecular and proteomic tests may qualify
for Medicare coverage after a solid organ transplant. It covers both surveillance
testing and testing used when there is concern about possible rejection.

The decision reduces uncertainty around the reimbursement pathway for advanced transplant
diagnostics. Clearer coverage criteria can support adoption by laboratories and 
clinicians, while giving diagnostic companies a more defined framework for clinical
evidence, testing frequency and appropriate use.

The policy recognises that molecular testing can support decisions across the post-
transplant pathway. Tests may be used to assess active rejection, evaluate whether
immunosuppression is adequate, monitor response to treatment and help determine 
whether a biopsy is needed. They may also provide additional information when biopsy
results are unclear or do not match the wider clinical picture.

The final determination also allows surveillance testing in patients who do not 
show clear signs of rejection. This is important because changes in graft health
may occur before symptoms become obvious. Earlier molecular insight may help clinicians
identify risk sooner and adjust patient management where appropriate.

Coverage is subject to analytical validity, clinical validity and clinical utility
requirements. Tests must also complete a MolDx Technical Assessment. These conditions
maintain a clear evidence threshold and favour companies able to support their products
with strong clinical validation.

Kidney transplant recipients may be tested at up to six timepoints during the first
year after transplant. Heart and lung transplant recipients may be tested at up 
to 12 timepoints during the same period. Testing may continue at a lower frequency
after the first year where supported by evidence and clinical guidance.

The LCD also places limits on unnecessary duplication. In most cases, only one molecular
test may be used for a patient encounter. Molecular testing and biopsy at the same
time are expected to be reserved for limited situations where both are clinically
justified.

_**[Verici Dx Plc](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)**(
LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests
forming a kidney transplant diagnostics platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient outcomes._

Share on:
